Matches in SemOpenAlex for { <https://semopenalex.org/work/W2765169245> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W2765169245 endingPage "A939" @default.
- W2765169245 startingPage "A938" @default.
- W2765169245 abstract "To assess the cost-utility of secukinumab in the treatment of ankylosing spondylitis (AS) patients in Colombia versus TNF-α inhibitors The cost-effectiveness model captures health benefits (measured by quality-adjusted life years [QALYs]) and costs associated with the use of secukinumab and TNF-α inhibitors over time horizons of 1 and 10 years in two subgroups of patients regarding the previous use of biologics: naive and experienced. A Markov model captured treatment effects on Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Bath Ankylosing Spondylitis Functional Index (BASFI) using relative treatment response rates for technologies from a network meta-analysis including MEASURE2 trial for secukinumab. Patient quality of life was based on an algorithm linking BASDAI and BASFI scores, gender and age to utilities. Probabilities of shift, maintenance or discontinuation, depend on BASDAI and BASFI results. Costs include those of drugs, procedures, relevant adverse events, and are measured in Colombian Pesos from third payer perspective based in national public databases and tariffs. According to the base case for 1 and 10 years, secukinumab turned out to be dominant (more effective and less costly) versus certolizumab pegol, etanercept and adalimumab for both patient subgroups. Long-term incremental QALYs for biologic naïve patients with secukinumab versus certolizumab pegol, etanercept and adalimumab were 0.099, 0.164 and 0.046, respectively and incremental cost were -$28,472,133, -$27,696,705 and -$39,077,037, respectively. Versus infliximab and golimumab, secukinumab is less costly, but minimally less effective than these alternative treatments, for both subgroups of patients and both time horizons. The use of secukinumab turns out to be a therapy with better results in terms of quality of life and lower treatment costs for ankylosing spondylitis patients versus most currently used TNF-α inhibitors in Colombia, thus it is recommended to be reimbursed by the Colombian healthcare system." @default.
- W2765169245 created "2017-11-10" @default.
- W2765169245 creator A5002469369 @default.
- W2765169245 creator A5034584000 @default.
- W2765169245 creator A5063712116 @default.
- W2765169245 creator A5081338074 @default.
- W2765169245 date "2017-10-01" @default.
- W2765169245 modified "2023-09-29" @default.
- W2765169245 title "Cost-Utility Analysis of Secukinumab use Versus Tnf-Α Inhibitors, in Patients with Ankylosing Spondilytis" @default.
- W2765169245 doi "https://doi.org/10.1016/j.jval.2017.08.2980" @default.
- W2765169245 hasPublicationYear "2017" @default.
- W2765169245 type Work @default.
- W2765169245 sameAs 2765169245 @default.
- W2765169245 citedByCount "1" @default.
- W2765169245 countsByYear W27651692452018 @default.
- W2765169245 crossrefType "journal-article" @default.
- W2765169245 hasAuthorship W2765169245A5002469369 @default.
- W2765169245 hasAuthorship W2765169245A5034584000 @default.
- W2765169245 hasAuthorship W2765169245A5063712116 @default.
- W2765169245 hasAuthorship W2765169245A5081338074 @default.
- W2765169245 hasBestOaLocation W27651692451 @default.
- W2765169245 hasConcept C112930515 @default.
- W2765169245 hasConcept C126322002 @default.
- W2765169245 hasConcept C17991360 @default.
- W2765169245 hasConcept C1862650 @default.
- W2765169245 hasConcept C2776215756 @default.
- W2765169245 hasConcept C2776260265 @default.
- W2765169245 hasConcept C2777138892 @default.
- W2765169245 hasConcept C2777226972 @default.
- W2765169245 hasConcept C2777402515 @default.
- W2765169245 hasConcept C2777453003 @default.
- W2765169245 hasConcept C2778715236 @default.
- W2765169245 hasConcept C2778975655 @default.
- W2765169245 hasConcept C2779134260 @default.
- W2765169245 hasConcept C2779786854 @default.
- W2765169245 hasConcept C2780132546 @default.
- W2765169245 hasConcept C2780415856 @default.
- W2765169245 hasConcept C2781290027 @default.
- W2765169245 hasConcept C3019080777 @default.
- W2765169245 hasConcept C64332521 @default.
- W2765169245 hasConcept C71924100 @default.
- W2765169245 hasConceptScore W2765169245C112930515 @default.
- W2765169245 hasConceptScore W2765169245C126322002 @default.
- W2765169245 hasConceptScore W2765169245C17991360 @default.
- W2765169245 hasConceptScore W2765169245C1862650 @default.
- W2765169245 hasConceptScore W2765169245C2776215756 @default.
- W2765169245 hasConceptScore W2765169245C2776260265 @default.
- W2765169245 hasConceptScore W2765169245C2777138892 @default.
- W2765169245 hasConceptScore W2765169245C2777226972 @default.
- W2765169245 hasConceptScore W2765169245C2777402515 @default.
- W2765169245 hasConceptScore W2765169245C2777453003 @default.
- W2765169245 hasConceptScore W2765169245C2778715236 @default.
- W2765169245 hasConceptScore W2765169245C2778975655 @default.
- W2765169245 hasConceptScore W2765169245C2779134260 @default.
- W2765169245 hasConceptScore W2765169245C2779786854 @default.
- W2765169245 hasConceptScore W2765169245C2780132546 @default.
- W2765169245 hasConceptScore W2765169245C2780415856 @default.
- W2765169245 hasConceptScore W2765169245C2781290027 @default.
- W2765169245 hasConceptScore W2765169245C3019080777 @default.
- W2765169245 hasConceptScore W2765169245C64332521 @default.
- W2765169245 hasConceptScore W2765169245C71924100 @default.
- W2765169245 hasIssue "9" @default.
- W2765169245 hasLocation W27651692451 @default.
- W2765169245 hasOpenAccess W2765169245 @default.
- W2765169245 hasPrimaryLocation W27651692451 @default.
- W2765169245 hasRelatedWork W2202409929 @default.
- W2765169245 hasRelatedWork W2270992578 @default.
- W2765169245 hasRelatedWork W2765169245 @default.
- W2765169245 hasRelatedWork W2793165102 @default.
- W2765169245 hasRelatedWork W2793571749 @default.
- W2765169245 hasRelatedWork W2912302362 @default.
- W2765169245 hasRelatedWork W2994641445 @default.
- W2765169245 hasRelatedWork W2994841104 @default.
- W2765169245 hasRelatedWork W4255968620 @default.
- W2765169245 hasRelatedWork W4283710071 @default.
- W2765169245 hasVolume "20" @default.
- W2765169245 isParatext "false" @default.
- W2765169245 isRetracted "false" @default.
- W2765169245 magId "2765169245" @default.
- W2765169245 workType "article" @default.